retatrutide clinical trials efficacy (RETA) is one of the most promising investigational peptides in obesity research—but one important question deserves more attention: Can it affect birth control? Current evidence shows that GLP-1 receptor agonists slow Lilly's retatrutide shows 28% weight

At the same time, it is becoming increasingly apparent that today it is not just about weight loss per se

Zambrano-Vsquez, Fernando Corts-Camacho, Jorge I

When activated by GLP-1 agonists, these receptors dampen the reward signal, making the substance less neurochemically compelling

NIH-cited analysis indicates berberine appears to activate AMPK (a key metabolic signaling enzyme) and has been associated with GLP-1 pathway activity in animal models and some human data

Drug classes to be on the lookout for are outlined in Table 2 , and include several major buckets: Incretins Plus : these assets often add additional agonism to the classic GLP-1 or GLP-1/GIP drugs

However, nearly 60 plaintiffs have now alleged that these medications led to stomach paralysis or other severe conditions